Cargando…
替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究
OBJECTIVE: To investigate the relationship between M2-polarized macrophages and early response in multiple myeloma and its molecular mechanism. METHODS: Two hundred and forty bone marrow biopsy tissue were collected and M2-polarized macrophages were stained by anti-CD163 monoclonal antibody. In vitr...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342963/ https://www.ncbi.nlm.nih.gov/pubmed/28655090 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.004 |
_version_ | 1783555649277263872 |
---|---|
collection | PubMed |
description | OBJECTIVE: To investigate the relationship between M2-polarized macrophages and early response in multiple myeloma and its molecular mechanism. METHODS: Two hundred and forty bone marrow biopsy tissue were collected and M2-polarized macrophages were stained by anti-CD163 monoclonal antibody. In vitro M2-polarized macrophages were derived from human peripheral blood mononuclear cell or THP-1 cells and identified by flow cytometry. Two myeloma cell lines RPMI 8226 and U266 were co-cultured with M2 macrophages using a transwell system. We measured myeloma cells proliferation through CCK-8 method and the pro-inflammatory cytokines expression (TNF-α and IL-6) by ELISA. Real time PCR was applied to measure chemokines (CCL2 and CCL3), chemokine receptors (CCR2, CCR5), VEGF and their receptors. In addition, flow cytometry was used to analyze the apoptosis of myeloma cells induced by dexamethasone. RESULTS: ①Patients with high percentage of M2 macrophage involvement in bone marrow showed poorer response (23.9% versus 73.0%, χ(2)=60.31, P<0.001). ②In vitro the proliferation of RPMI 8226 cells (P=0.005 at 24 h, P=0.020 at 36 h) or U266 myeloma cells (P= 0.030 at 24h, P=0.020 at 36h) co-cultured with M2-polarized macrophages was higher than control group. ③In vitro the apoptotic rate of RPMI 8226 cells (29.0% versus 71.0%, t=4.97, P=0.008) or U266 myeloma cells (24.9% versus 67.7%, t=6.99, P=0.002) co-cultured with M2-polarized macrophages was lower than control group. ④In vitro M2-polarized macrophages promoted myeloma cells secreting higher level of IL-6, TNF-α and higher expression of CCL2, CCL3, CCR2, CCR5, VEGFA, VEGFR-1,-2 compared with the non-macrophage co-culture system. CONCLUSION: M2-polarized macrophages promote myeloma cells proliferation and inhibit apoptosis through a very complex mechanism involving pro-inflammatory cytokines IL-6 and TNF-α, chemokines and related receptors such as CCL2, CCL3, CCR2, CCR3, and VEGF as well as related VEGFR. |
format | Online Article Text |
id | pubmed-7342963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73429632020-07-16 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the relationship between M2-polarized macrophages and early response in multiple myeloma and its molecular mechanism. METHODS: Two hundred and forty bone marrow biopsy tissue were collected and M2-polarized macrophages were stained by anti-CD163 monoclonal antibody. In vitro M2-polarized macrophages were derived from human peripheral blood mononuclear cell or THP-1 cells and identified by flow cytometry. Two myeloma cell lines RPMI 8226 and U266 were co-cultured with M2 macrophages using a transwell system. We measured myeloma cells proliferation through CCK-8 method and the pro-inflammatory cytokines expression (TNF-α and IL-6) by ELISA. Real time PCR was applied to measure chemokines (CCL2 and CCL3), chemokine receptors (CCR2, CCR5), VEGF and their receptors. In addition, flow cytometry was used to analyze the apoptosis of myeloma cells induced by dexamethasone. RESULTS: ①Patients with high percentage of M2 macrophage involvement in bone marrow showed poorer response (23.9% versus 73.0%, χ(2)=60.31, P<0.001). ②In vitro the proliferation of RPMI 8226 cells (P=0.005 at 24 h, P=0.020 at 36 h) or U266 myeloma cells (P= 0.030 at 24h, P=0.020 at 36h) co-cultured with M2-polarized macrophages was higher than control group. ③In vitro the apoptotic rate of RPMI 8226 cells (29.0% versus 71.0%, t=4.97, P=0.008) or U266 myeloma cells (24.9% versus 67.7%, t=6.99, P=0.002) co-cultured with M2-polarized macrophages was lower than control group. ④In vitro M2-polarized macrophages promoted myeloma cells secreting higher level of IL-6, TNF-α and higher expression of CCL2, CCL3, CCR2, CCR5, VEGFA, VEGFR-1,-2 compared with the non-macrophage co-culture system. CONCLUSION: M2-polarized macrophages promote myeloma cells proliferation and inhibit apoptosis through a very complex mechanism involving pro-inflammatory cytokines IL-6 and TNF-α, chemokines and related receptors such as CCL2, CCL3, CCR2, CCR3, and VEGF as well as related VEGFR. Editorial office of Chinese Journal of Hematology 2017-06 /pmc/articles/PMC7342963/ /pubmed/28655090 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.004 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title_full | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title_fullStr | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title_full_unstemmed | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title_short | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
title_sort | 替代活化型巨噬细胞和多发性骨髓瘤早期治疗反应的关系及机制研究 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342963/ https://www.ncbi.nlm.nih.gov/pubmed/28655090 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.004 |
work_keys_str_mv | AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū AT tìdàihuóhuàxíngjùshìxìbāohéduōfāxìnggǔsuǐliúzǎoqīzhìliáofǎnyīngdeguānxìjíjīzhìyánjiū |